At a glance
ClinicalIndex Comparison RecordN/ACompleted· 669 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
POST MARKETING SURVEILLANCE TO OBSERVE THE SAFETY AND EFFICACY OF DUAVIVE TAB 0.45MG/20MG
In Brief
An observational study for Severe Vasomotor Symptom Associated With Menopause. Completed, enrolled 669 participants across 20 sites.
Detailed Summary
To evaluate safety and efficacy of CE/BZA in real practice in Korea
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedJun 2016
Primary CompletionJul 2020
TodayJul 2026
First PostedJun 7, 2016
Enrollment StartMar 29, 2016
Primary CompletionJul 22, 2020
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 10.1 years ago